

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **COMPLETION OF MAJOR TRANSACTION IN RELATION TO THE ACQUISITION OF 100% OF THE ISSUED SHARES IN THE TARGET COMPANIES INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE**

Reference is made to the announcements of China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 28 April 2025, 29 April 2025 and 18 December 2025, and the circular of the Company dated 24 December 2025 (the “**Circular**”), in relation to, among others, the major transaction in relation to the acquisition of 100% of the issued shares in the Target Companies involving the issue of Consideration Shares under Specific Mandate. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Circular.

### **COMPLETION OF THE ACQUISITION**

The Board is pleased to announce that the Company has allotted and issued 274,751,679 new Shares to the 8 Sellers at the issue price of HK\$0.45 per Consideration Share on 25 March 2026 to complete the payment of the Consideration, and all the conditions precedent to the Sale and Purchase Agreement and the Supplemental Agreement set out in the section headed “Conditions” of the Circular have been fulfilled. The 100% issued shares in the 3 Target Companies involved in the Transaction have been transferred and registered in the name of the Company, and the Target Companies have become indirect wholly-owned subsidiaries of the Company. Upon Completion of the Acquisition, the Company indirectly holds 58.11% equity interest in Zhejiang Kangyuan Medical Equipment Co., Ltd.\* through its wholly-owned subsidiaries, and its financial results will be consolidated into the accounts of the Group.

## EFFECT ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

Details of the shareholding structure of the Company immediately before and immediately after the issue of the Consideration Shares are set out below:

Name of Shareholder	Immediately before the Completion		Immediately after the Completion	
	<i>Approximate % of the number</i>		<i>Approximate % of the number</i>	
	<i>Number of Shares</i>	<i>of Shares in issue</i>	<i>Number of Shares</i>	<i>of Shares in issue</i>
Golden Base Investment Ltd <sup>(1)</sup>	303,925,563	45.08	303,925,563	32.03
Ms. Chin Yu	273,333	0.04	273,333	0.03
Mr. Jeong Iat <sup>(2)</sup>	146,520,146	21.73	146,520,146	15.44
Mr. Jeong Chong Meng	54,762,300	8.12	54,762,300	5.77
Annie Investment Co., Ltd.	170,000	0.03	170,000	0.02
Mr. Yu Tze Shan Hailson <sup>(3)</sup>	15,000	0	15,000	0
Mr. Lou YongBin <sup>(4)(5)</sup>	–	–	61,073,627	6.43
Mr. Lou YongJun <sup>(4)(5)</sup>	–	–	47,328,267	4.99
Ms. Chen HongLi <sup>(4)(5)</sup>	–	–	80,326,240	8.46
Mr. Zhang GenHuo <sup>(4)(5)</sup>	–	–	79,399,732	8.37
Mr. Zhang LiLiang <sup>(4)(5)</sup>	–	–	2,365,647	0.25
Ms. He XianHua <sup>(4)(5)</sup>	–	–	1,892,518	0.2
Ms. Hu BaoZhen <sup>(4)(5)</sup>	–	–	1,892,518	0.2
Ms. Zheng Min <sup>(4)(5)</sup>	–	–	473,130	0.05
Other public shareholders <sup>(5)</sup>	168,579,673	25.00	168,579,673	17.76
Total number of issued Shares	<u>674,246,015</u>	<u>100.00</u>	<u>948,997,694</u>	<u>100.00</u>

Notes:

- (1) Golden Base Investment Limited is legally and beneficially owned as to 50% by Ms. Chin Yu and 50% by Mr. Ng Tit, the spouse of Ms. Chin Yu.
- (2) Mr. Jeong Iat is the son of Mr. Jeong Chong Meng and Ms. Shum Ning, who wholly owns Annie Investment Co. Ltd.
- (3) Mr. Yu Tze Shan Hailson is an independent non-executive Director of the Company.

- (4) Save as Mr. Lou YongBin and Mr. Lou YongJun being brothers, there is no other voting or acting in concert arrangements or agreements among the Sellers.
- (5) Shares counted towards the public float of the Company.

By order of the Board  
**China NT Pharma Group Company Limited**  
*Chairman*  
**NG Tit**

Hong Kong, 25 March 2026

*As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng, Anna Ching Mei; the non-executive Directors are Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Ng Ming Kwan and Dr. Zhao Yubiao.*

*\* For identification purposes only*